Russian Patient Successfully Cured of Follicular Lymphoma(FL) with CAR-T Therapy in China!

**Patient Story – Oleg’s Cancer Journey:**

Today, we share the story of a 46-year-old patient from Russia named Oleg. Oleg was diagnosed with follicular lymphoma and, after multiple rounds of chemotherapy, achieved complete remission. Unfortunately, the disease relapsed, with several enlarged lymph nodes appearing in his abdomen and other areas. Faced with this resurgence, Oleg was determined not to give up and decided to seek new treatment options to improve his quality of life.

**Tailor-Made CAR-T Treatment Plan:**

After extensive research, Oleg contacted us and connected with lymphoma experts from our Advanced Medicine in China team. Through video consultations and detailed discussions, he decided to pursue CAR-T cell therapy. With confidence in the potential of Chinese CAR-T therapy, Oleg and his family traveled thousands of miles to China to begin his CAR-T treatment journey.

Given Oleg’s high tumor burden and relapse after chemotherapy, the Chinese medical team customized a bridging therapy for him, combining targeted drugs with low-dose radiotherapy to reduce the tumor burden and improve the immune environment. Special care was taken when designing the radiotherapy plan, as Oleg still had fertility concerns. The team created a personalized treatment plan that balanced safety and effectiveness. During the treatment process, Oleg experienced almost no significant side effects, demonstrating excellent treatment compliance and tolerance. He maintained a strong relationship of trust and communication with the medical team.

**Complete CR – A New Life After Treatment**

Oleg’s CAR-T cell infusion process went smoothly. Despite a history of migraines, he only experienced mild headaches and low-grade fever after the treatment. Under the meticulous care of the treatment team, the CAR-T cells demonstrated strong anti-tumor effects, with minimal side effects. For a patient with a high tumor burden, he only developed grade 1 cytokine release syndrome (CRS), and his blood counts began to recover about a week after the infusion. Overall, he remained in good condition.

Fifteen days after the CAR-T infusion, an abdominal ultrasound showed significant shrinkage of the enlarged lymph nodes. Three months later, a PET-CT scan brought even more surprising news—Oleg’s tumors had completely disappeared, and his response was evaluated as a complete remission (CR). This meant that Oleg had beaten cancer!

Today, Oleg is doing better and better, running daily. He is especially grateful for the support and care provided by the Advanced Medicine in China team and the Chinese experts. Despite being far from home, he never felt inconvenienced during his treatment in China. The doctors and nurses not only communicated with him patiently but also provided significant help in his daily life.

**Why Choose CAR-T Treatment in China?**

CAR-T therapy has shown remarkable efficacy in treating relapsed and refractory follicular lymphoma, with clinical data showing an objective response rate (ORR) of over 90% and a median duration of response exceeding three years! Oleg’s case is a testament to China’s advanced medical technology. Traditional chemotherapy tends to lose effectiveness after repeated treatments, while CAR-T therapy offers the possibility of curing diseases like follicular lymphoma, which were previously considered incurable.

For patients like Oleg, who seek a high-quality life, China’s CAR-T therapy is bringing new hope.

**World-Class – China’s CAR-T Indications and Beyond**

Today, China’s CAR-T is not only actively involved in global research but is also leading many developments in the CAR-T field. For patients like Oleg with follicular lymphoma, only China and the U.S. have approved CAR-T products targeting this condition. However, China’s CR rate is notably higher.

Currently, China offers the most extensive range of CAR-T indications, including relapsed or refractory diffuse large B-cell lymphoma (DLBCL) for first-line, second-line, or third-line treatment failures or relapse; relapsed follicular lymphoma (FL) after second-line treatment; mantle cell lymphoma (MCL) with multiple treatment failures; unspecified DLBCL; large B-cell lymphoma transformed from FL; primary mediastinal large B-cell lymphoma; and high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CART #CancerTreatment #AdvancedMedicineInChina #Lymphoma #FollicularLymphoma #CancerRemission #MedicalTourism #ChinaCare #HealingJourney #CancerFree #Immunotherapy #GlobalHealthcare